Canadian Markets open in 4 hrs 47 mins

CTI BioPharma Corp. (CTIC)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.41-0.12 (-3.40%)
At close: 4:00PM EDT
People also watch
HEBAGENXOMAKERXGERN
Full screen
Previous Close3.53
Open3.51
Bid3.45 x 100
Ask3.49 x 1400
Day's Range3.33 - 3.54
52 Week Range0.32 - 6.48
Volume215,709
Avg. Volume102,466
Market Cap146.63M
Beta0.62
PE Ratio (TTM)-1.27
EPS (TTM)-2.69
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Trade prices are not sourced from all markets
  • CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
    PR Newswire3 hours ago

    CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors

    SEATTLE, July 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed a Director of CTI BioPharma effective July 21, 2017. Dr. Fischer  has more than 20 years experience in developing and commercializing novel medicines in the biopharmaceutical industry and currently serves as liver therapeutic area head at Allergan following its acquisition of Tobira Therapeutics in 2016 where he previously served as Chief Executive Officer.

  • CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
    PR Newswire11 days ago

    CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia

    SEATTLE, July 13, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). Validation confirms that the submission is complete and initiates the centralized review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).  The CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on EU authorization within three months. If authorized, pacritinib would be granted a marketing license valid in all 28 EU member states.

  • PR Newswirelast month

    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    SEATTLE , June 15, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to ...